Japan's Takeda Pharmaceutical will scale up production of its dengue vaccine Qdenga through a partnership with Indian vaccines maker Biological E., the companies said on Tuesday. These doses will be available for governments in endemic countries by 2030 as part of their national immunization programmes. Biological E. will ramp up to a manufacturing capacity of 50 million doses a year, accelerating Takeda's efforts to produce 100 million doses per year within a decade, the companies said.
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") contributed to the development of a pediatric formulation to treat schistosomiasis as a member of the Pediatric Praziquantel Consortium (Consortium). The Consortium announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive scientific opinion for arpraziquantel to treat one of the neglected tropical diseases, schistosomiasis, in preschool-aged chi
Major boost to progress in tuberculosis testing on World Tuberculosis (TB) Day as diagnostics partners bring together SMART4TB, DriveDx4TB, FEND-TB and R2D2 TB Network projects
KABUL Several people were wounded following a bicycle bomb explosion in the central part of Kabul, the capital of Afghanistan on Monday, the capital police c